Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced a collaboration with SoundHealth to distribute SoundHealth’s FDA-cleared Sonu® Band and new Spatial Sleep™ band across Vivos’ clinical network. Vivos will resell the devices and gain access to SoundHealth’s CT-accurate smartphone facial scanning and voice biomarker technology to aid screening, treatment, and monitoring of airway and sleep disorders.
The partnership leverages Vivos’ network of over 2,000 Vivos-trained dentists and sleep providers and aims to expand access to personalized, non-drug airway and sleep therapies.
Positive
- Access to >2,000 Vivos-trained dentists and sleep providers for product distribution
- Reseller agreement to distribute FDA-cleared Sonu Band and new Spatial Sleep band
- Integration of CT-accurate smartphone facial scanning and voice biomarkers for screening and monitoring
- Sonu Band described as clinically proven to match intranasal steroids without side effects
Negative
- None.
News Market Reaction – VVOS
On the day this news was published, VVOS declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +11.3% during that session. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows 1 peer (e.g., IINN) moving down 12.96% with no peers up, while broader medical device peers show mixed single-digit moves, suggesting stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Warrant exercise closing | Negative | -4.8% | Closing of warrant exercise for about $4.64M gross proceeds at reduced price. |
| Jan 16 | Warrant inducement deal | Negative | -3.3% | Agreement for immediate warrant exercise and issuance of new private warrants. |
| Dec 16 | Sleep center opening | Positive | +0.0% | Opening of affiliated sleep testing and treatment center in Auburn Hills, Michigan. |
| Dec 15 | Investor fireside chat | Neutral | -2.4% | Announcement of online fireside chat to discuss strategy and growth plans. |
| Nov 19 | Q3 2025 results | Positive | -4.5% | Report of Q3 revenue growth to $6.8M, up 76% year-over-year with higher losses. |
Recent capital-raising announcements have seen negative price reactions, while operational news has often failed to lift the stock.
Over the last few months, Vivos has combined financing actions with operational expansion. Two January warrant exercises raised about $4.64M each in gross proceeds but coincided with 3–5% single-day declines. Earlier, Vivos opened an affiliated sleep center near Detroit and highlighted its strategic pivot and strong Q3 2025 revenue growth to $6.8M, yet those updates produced flat to slightly negative moves. Today’s collaboration news extends the sleep and airway ecosystem focus along the same strategic line.
Regulatory & Risk Context
The company has an active Form S-3/A shelf filed on 2025-09-05 with at least two subsequent prospectus uses (424B3 and 424B5), indicating an established mechanism for future registered offerings.
Market Pulse Summary
This announcement expands Vivos’ portfolio with FDA-cleared, AI-enabled allergy and sleep wearables distributed through its network of over 2,000 providers. It reinforces the shift toward active airway interventions in a roughly $30 billion sleep technology market where about 80% of sleep‑disordered breathing cases are cited as undiagnosed. In context of recent warrant financings and going‑concern disclosures, investors may watch how this collaboration translates into revenue growth and utilization across new and existing sleep centers.
Key Terms
fda-cleared regulatory
vibro-acoustic neuromodulation medical
craniofacial medical
biomarker medical
cpap medical
neural entrainment medical
airway interventions medical
AI-generated analysis. Not financial advice.
Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market
LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth’s consumer-focused airway and sleep health technologies.
The collaboration leverages Vivos’ extensive national network of over 2,000 Vivos-trained dentists and sleep healthcare providers, along with affiliated sleep testing centers in select markets, to distribute SoundHealth’s Sonu® platform, including the FDA-cleared Sonu® Band and the newly released Spatial Sleep™ band. Both devices use personalized vibro-acoustic neuromodulation to harness the body’s natural mechanisms to enable clear nasal breathing and promote deep, restful sleep.
SoundHealth possesses the world’s largest craniofacial dataset for sino-nasal and airway health. The collaboration with Vivos will harness this dataset and SoundHealth’s innovative technology to explore educational and distribution initiatives across Vivos’ large provider network to promote airway health awareness and treatment as a foundational component of sleep and overall wellness. Vivos will act as a reseller of these products across its network. As part of the collaboration, Vivos will have access to SoundHealth’s CT-accurate smartphone camera-based facial scanning and voice biomarker technology to aid its vast network of clinical providers in the screening, treatment, and monitoring of sleep disorders.
SoundHealth Products
Sonu Band is the world’s first and only FDA-cleared, clinically proven AI-enabled wearable to treat nasal congestion due to allergic and non-allergic rhinitis on par with intranasal steroids, with zero side effects, and was named as one of TIME’s best inventions of 2025. Sonu has also been clinically proven to help CPAP users increase their compliance and adherence.
The Spatial Sleep band’s personalized acoustic resonance therapy has been clinically proven to promote rapid sleep onset and deeper and longer periods of sleep by using active neural entrainment.
Both devices use smartphone front-facing cameras to construct a CT-quality anatomical model of a user’s craniofacial anatomy. This personalized model is then used to generate a customized vibratory therapeutic stimulus.
The Sonu smartphone app also pioneers the use of voice biomarkers, along with facial anatomy, to track airway health in real time, helping providers and therapists actively monitor patients throughout their therapeutic journey.
“Our Sonu platform was built to give people a practical, non-invasive way to help people breathe and sleep using FDA-cleared cutting edge drug free technology,” said Paramesh Gopi, CEO of Sound Health. “This aligns perfectly with Vivos’ mission, and we are excited to collaborate with Vivos to bring our technology and data science to their providers and sleep and airway clinics.”
Kirk Huntsman, CEO of Vivos Therapeutics, said, “SoundHealth’s advanced technology across multiple product offerings is perfectly synergistic with Vivos treatment technology. We believe this collaboration will add value-added products to our existing offerings and allow Vivos to maintain its global leadership position in offering sleep, breathing, and now allergy patients the most advanced and effective non-invasive treatments available today for these debilitating disorders. Even in our initial rollout, Vivos providers using Sound Health products report high levels of patient satisfaction and are enthusiastic about expanding access and exposure.”
This focus on airway health addresses urgent medical realities; according to the American Heart Association, untreated sleep-disordered breathing is associated with a
“We are witnessing a fundamental shift in the approximately
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to the actual future impact on Vivos’ revenue and profitability from its reseller collaboration with SoundHealth as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual results from the collaboration with SoundHealth) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable effectively market or sell SoundHealth’s products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ or SoundHealth’s products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries: Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
FAQ
What will Vivos (VVOS) distribute under its collaboration with SoundHealth on Feb 5, 2026?
How large is Vivos’ provider network for distributing SoundHealth products (VVOS)?
What clinical and regulatory status do the Sonu Band and Spatial Sleep band have for VVOS investors?
How will SoundHealth’s technology assist Vivos clinicians in patient care for VVOS shareholders?
What patient benefits do SoundHealth devices claim to provide that could affect VVOS adoption?
